Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

This study has been completed.
Information provided by (Responsible Party):
Daiichi Sankyo Inc. Identifier:
First received: September 9, 2005
Last updated: January 16, 2012
Last verified: January 2012
A comparison of 2 different combinations of high blood pressure medications to treat hypertension

Condition Intervention Phase
Drug: Olmesartan medoxomil
Drug: Hydroclorothiazide
Drug: Benazepril
Drug: Amlodipine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • Change in systolic blood pressure from the start of the study

Secondary Outcome Measures:
  • Change in diastolic blood pressure from the start of the study
  • Percent of patients who achieve target blood pressure goals

Estimated Enrollment: 152
Study Start Date: September 2005
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Greater than 18 years of age
  • Patients with high blood pressure

Exclusion Criteria:

  • Hypertensive encephalopathy, stroke or transient ischemic attack within the past 6 months
  • History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
  • Type 1 diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00185120

United States, Alabama
Mobile, Alabama, United States, 36693
United States, California
Memorial Research Medical Center
Long Beach, California, United States, 90806
National Research Institute
Los Angeles, California, United States, 90057
Clinical Trials Research
Roseville, California, United States, 95661
Apex Research Institute
Santa Ana, California, United States, 92705
Orange County Research Center
Tustin, California, United States, 92780
Westlake Medical Center
Westlake Village, California, United States, 91361
United States, Florida
Clinical Research of South Florida
Coral Gables, Florida, United States, 33134
The Greater Fort Lauderdale Heart Group Research
Fort lauderdale, Florida, United States, 33308
SFBC International
Miami, Florida, United States, 33142
Tamarac, Florida, United States, 33321
United States, Indiana
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States, 46260
United States, Kansas
Heartland Research Associates
Wichita, Kansas, United States, 67207
United States, Maine
Androscoggin Cardiology Research
Auburn, Maine, United States, 04210
United States, North Carolina
Internal Medicine Associates of Charlotte
Charlotte, North Carolina, United States, 28211
Piedmont Medical Research Associates
Winston-salem, North Carolina, United States, 27103
United States, Ohio
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States, 45319
United States, Rhode Island
Omega Medical Research
Warwick, Rhode Island, United States, 02886
United States, Tennessee
Volunteer Research Group, University of Tennessee Med. Ctr.
Knoxville,, Tennessee, United States, 37920
United States, Texas
Punzi Medical Center
Carrollton, Texas, United States, 75006
Sponsors and Collaborators
Daiichi Sankyo Inc.
  More Information

Responsible Party: Daiichi Sankyo Inc. Identifier: NCT00185120     History of Changes
Other Study ID Numbers: 866-447 
Study First Received: September 9, 2005
Last Updated: January 16, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Daiichi Sankyo Inc.:
angiotensin receptor blocker
calcium channel blocker
angiotensin converting enzyme inhibitor hydroclorothiazide

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Calcium Channel Blockers
Olmesartan Medoxomil
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Enzyme Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Protease Inhibitors
Sodium Chloride Symporter Inhibitors processed this record on May 30, 2016